<div id="readability-page-1"><p>Calamos Wealth Management LLC lessened its holdings in  Zoetis Inc. (NYSE:ZTS - Free Report) by 97.2% during the 3rd quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The firm owned 2,414 shares of the company's stock after selling 84,733 shares during the period. Calamos Wealth Management LLC's holdings in Zoetis were worth $353,000 at the end of the most recent reporting period.</p><ul><li>Which Pet Stock Should Get Your Tail Wagging in 2024?</li></ul><p>Several other large investors also recently added to or reduced their stakes in the business. Nova Wealth Management Inc. purchased a new position in  Zoetis during the first quarter valued at approximately $25,000.  Halbert Hargrove Global Advisors LLC raised its position in shares of  Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company's stock valued at $25,000 after purchasing an additional 144 shares during the period.  REAP Financial Group LLC lifted its stake in shares of  Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company's stock valued at $31,000 after buying an additional 131 shares in the last quarter.  NewSquare Capital LLC boosted its holdings in  Zoetis by 69.1% in the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company's stock worth $32,000 after buying an additional 85 shares during the period.  Finally, 1248 Management LLC purchased a new stake in  Zoetis in the 1st quarter worth $35,000. 92.80% of the stock is currently owned by institutional investors. </p><h2>Zoetis Stock Performance</h2><p>Shares of NYSE:ZTS opened at $125.82 on Thursday. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $177.40. The company has a market capitalization of $55.45 billion, a price-to-earnings ratio of 21.18, a PEG ratio of 2.75 and a beta of 0.97. The firm's 50-day moving average is $125.84 and its 200 day moving average is $142.13. </p><ul><li>MarketBeat Week in Review – 07/31 - 08/04</li></ul><p>Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. During the same quarter in the previous year, the business earned $1.58 earnings per share. Zoetis's quarterly revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS.  Research analysts predict that  Zoetis Inc. will post 6.07 EPS for the current year. </p><h2>Zoetis Increases Dividend</h2><p>The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be issued a $0.53 dividend. This is an increase from Zoetis's previous quarterly dividend of $0.50. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend is Tuesday, January 20th. Zoetis's dividend payout ratio  is 33.67%. </p><h2>Wall Street Analysts Forecast Growth</h2><ul><li>Rising Dividend Make Zoetis a Doggone Winner</li></ul><p>ZTS has been the subject of several research analyst reports. Barclays began coverage on Zoetis in a research report on Monday, December 8th. They set an &#34;equal weight&#34; rating and a $136.00 target price for the company. The Goldman Sachs Group raised shares of Zoetis to a &#34;buy&#34; rating in a report on Monday, December 15th. KeyCorp started coverage on shares of Zoetis in a research report on Thursday, November 20th. They set a &#34;sector weight&#34; rating on the stock. Morgan Stanley  set a $160.00 target price on shares of Zoetis in a research report on Thursday, December 18th. Finally, Weiss Ratings  reaffirmed a &#34;sell (d+)&#34; rating on shares of Zoetis in a research note on Monday. Six analysts have rated the stock with a Buy rating, seven have issued  a Hold rating and one  has given a Sell rating to the company's stock. According to MarketBeat, the stock  has an average rating of &#34;Hold&#34; and a consensus target price of $160.18.</p><p><b>Check Out Our Latest Stock Analysis on Zoetis</b></p><h2>Zoetis Company Profile</h2> (Free Report)<p>Zoetis Inc <span>NYSE: ZTS<span></span></span> is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.  </p><p>Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.</p><h2>See Also</h2><ul><li>Five stocks we like better than Zoetis</li><li>The Best $1 You'll Spend This Holiday Season</li><li>Holiday surprise: $1 gets you everything</li><li>America’s “most deplorable” Christmas sale</li><li>Market Panic: Trump Just Dropped a Bomb on Your Stocks</li><li>Your family's wealth expires in 2026?</li></ul><p><strong>Want to see what other hedge funds are holding ZTS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpUUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpUUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Zoetis Right Now?</h2><p>Before you consider Zoetis, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.</p><p>While Zoetis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Calamos Wealth Management LLC has significantly reduced its stake in Zoetis Inc. (NYSE:ZTS) by 97.2% in Q3, now holding only 2,414 shares valued at $353,000. Other investors have also adjusted their positions, with institutional investors owning 92.80% of the stock. Zoetis recently reported Q3 earnings of $1.70 EPS, exceeding estimates, and announced a dividend increase to $0.53 per share. Analysts have mixed ratings on the stock, with an average target price of $160.18.</p>

Calamos Wealth Management LLC Reduces Stock Position in Zoetis Inc. $ZTS